Pancreatic Cancer Research

ResearcherInstitut Gustave RoussyActive in the last 2 years

Anthony Tarabay

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3804-3554; OpenAlex author ID A5104171125, A5107987762. Sources: OpenAlex.

Their work

Papers
11 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2023: 1 paper · 2024: 5 papers · 2025: 2 papers · 2026: 3 papers

Papers 11

  1. Metastatic pancreatic adenocarcinoma: Real-world efficacy of first line treatment. First author DOI 10.1016/j.ejca.2025.116160↗
  2. Lung-only metastatic pancreatic cancer: Differences in patients 'characteristics, molecular profile and survival. Co-author DOI 10.1016/j.ejca.2026.116227↗
  3. Integrating tumor volumetry and liquid biopsy: a New model to define prognosis in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.116768↗
  4. Precision medicine strategy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.esmoop.2025.105899↗
  5. Predictive factors of FOLFIRINOX chemotherapy toxicity in pancreatic adenocarcinoma patients. First author DOI 10.1080/14796694.2025.2461442↗
  6. Clinical and molecular features of early onset pancreatic adenocarcinoma. Co-author DOI 10.1002/ijc.35135↗
  7. Codon-specific KRAS mutations predict survival in advanced pancreatic cancer. Co-author DOI 10.1016/j.esmogo.2023.100030↗
  8. Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2024.05.032↗
  9. Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study. First author DOI 10.1186/s12885-024-12016-z↗
  10. Role of molecular biology in the management of pancreatic cancer. Co-author DOI 10.4251/wjgo.v16.i7.2902↗
  11. Precision Medicine in Pancreatic Ductal Adenocarcinoma: The Impact of Targeted Therapies on Survival of Patients Harboring Actionable Mutations. Co-author DOI 10.3390/biomedicines11092569↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Cristina Smolenschi · 11 shared papers, 2023–2026 · strength 2.13
  2. Antoine Hollebecque · 11 shared papers, 2023–2026 · strength 2.13
  3. Michel Pierre Ducreux · 11 shared papers, 2023–2026 · strength 2.13
  4. Alice Boilève · 10 shared papers, 2023–2026 · strength 1.94
  5. David Malka · 4 shared papers, 2023–2024 · strength 0.65
  6. Antoîne Italiano · 3 shared papers, 2024–2026 · strength 0.52
  7. Aurélien Lambert · 2 shared papers, 2024–2026 · strength 0.44
  8. Nathalie Lassau · 2 shared papers, 2025–2026 · strength 0.42
  9. Fanny Jaulin · 2 shared papers, 2024 · strength 0.30
  10. Mélanie Debiais · 1 shared paper, 2026 · strength 0.25
  11. Matthieu Delaye · 1 shared paper, 2026 · strength 0.24
  12. Victor Robic · 1 shared paper, 2026 · strength 0.22
  13. Étienne Rouleau · 1 shared paper, 2025 · strength 0.21
  14. Thierry Conroy · 1 shared paper, 2024 · strength 0.20
  15. Roland Eid · 1 shared paper, 2025 · strength 0.19
  16. Anna Gueiderikh · 1 shared paper, 2024 · strength 0.19
  17. Maxime Rémond · 1 shared paper, 2024 · strength 0.17
  18. Marc Hilmi · 1 shared paper, 2024 · strength 0.15
  19. Rémy Nicolle · 1 shared paper, 2024 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.